logo
The Largest Beef Recall To Hit The US, Explained

The Largest Beef Recall To Hit The US, Explained

Yahoo29-03-2025

The businesses that raise cattle and produce beef in the U.S. must adhere to strict rules and regulations. These rules not only protect consumers, but they also safeguard animals against needless cruelty, which is precisely what occurred in a California-based meat-packing facility in 2007. According to footage disseminated by the Humane Society, staff members at Hallmark Meat Packing plant were seen using brutal methods to cajole weakened, potentially sick cows to slaughter. This plant was providing meat to the Westland Meat Company, which in turn was distributing the beef to National School Lunch programs as well as families and elderly individuals in need.
The actions of Hallmark Meat Packing resulted in a massive recall of 143 million pounds of beef — the largest in the nation's history. Despite the recall, many potentially sick cows were slaughtered, and the resulting beef was distributed. Fortunately, no illnesses were linked to the meat prior to the animal abuse issue coming to light. While the incident doesn't rank among the most deadly recalled foods in American history (a list that does include Boar's Head deli meat and certain brands of cantaloupe), the cruelty exhibited toward the cattle was appalling and ultimately led to a massive judgement of $497 million, the highest amount ever awarded for animal abuse. Due to the expenses associated with the recall, Hallmark Meat Packing eventually filed for bankruptcy.
Read more: Sausage Brands Made With The Highest & Lowest Quality Ingredients
While the actions of the staff at Hallmark Meat Packing were inherently offensive, they also violated federal statutes. So-called "downer cattle" — cows that are incapable of standing — could be released for slaughter provided that Food Safety and Inspection Service veterinarians designated them safe for consumption after examination. This assessment of downer cattle was important for preventing contaminated meat from making its way into the food supply.
In particular, the risk of mad cow disease was especially worrisome due to the seriousness of these infections. Also known as bovine spongiform encephalopathy, mad cow is a type of prion disease that is fatal for cows, but it can also lead to variant Creutzfeldt-Jakob disease in humans (though the risk is admittedly small). Because Hallmark Meat Packing did not take the crucial step of having approved vets evaluate downer cattle prior to slaughter, the company was pressured to enact its voluntary recall by the Department of Agriculture. Additionally, the actions of the meat-packing facility led to a change in federal law mandating the culling of downer cattle in all circumstances.
The deplorable conditions at Hallmark/Westland meatpacking facility were a far cry from the recommended standards for animals. Many animal welfare advocates look to the five freedoms for guidance on these matters, standards established by British professor Roger Brambell in 1965. According to the five freedoms, animals must be free from hunger and thirst; free from discomfort; free from pain, injury, or disease; free to express normal behavior; and free from fear and distress.
While the five freedoms are British in origin, they're indispensable to numerous organizations, agencies, and groups. They also play a crucial role in audits and evaluations conducted at facilities where livestock is processed. According to the American Humane Society, the five freedoms represent a global "gold standard in animal welfare" because they ensure that an animal's basic needs are met while also establishing an environment that supports optimal physical and mental health.
Raising cattle humanely is simply the right thing to do from an ethical perspective, but it also offers many other benefits. Raising cattle on grass instead of grain reduces a beef producer's carbon footprint and helps maintain the natural ecosystem surrounding the cattle. Additionally, businesses can benefit from the use of humane methods because many consumers insist on buying products from companies that implement humane standards for animals.
Eliminating an animal's stress is also vital for preserving food safety. Stressed cattle have a higher chance of experiencing immune dysfunction, which can prevent animals from effectively fighting off diseases. While you're more likely to get food poisoning from produce than meat, decreased immune function in animals can raise the risk of infections caused by Campylobacter, E. coli, and Salmonella bacteria. Safeguarding cattle against stress can also reduce reliance on antibiotics, which are administered to cows as a safety precaution. Overuse of these medications in animals is associated with an increased risk of antibiotics resistance in humans, reducing the effectiveness of treatments for bacterial infections.
Read the original article on Mashed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaccine maker BioNTech to acquire fellow German pharma firm CureVac
Vaccine maker BioNTech to acquire fellow German pharma firm CureVac

Yahoo

time26 minutes ago

  • Yahoo

Vaccine maker BioNTech to acquire fellow German pharma firm CureVac

BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its German pharmaceutical rival CureVac, the firm said on Thursday. BioNTech, which is based in the south-western city of Mainz, is planning to purchase all CureVac shares in a billion-dollar transaction to expand its expertise in the field of mRNA-based cancer therapies, it said. As per the agreement, each CureVac share is to be sold for around $5.46, which would correspond to a valuation of the Tübingen-based company of approximately $1.25 billion. The completion of the acquisition is subject to regulatory approvals and is expected to close by the end of 2025, BioNTech said, with CureVac shareholders to hold between 4% and 6% of BioNTech as a result. Both firms, which are listed on New York's Nasdaq exchange, made headlines during the coronavirus pandemic when they joined the race to develop an effective vaccine against the virus. While CureVac failed to achieve a breakthrough, the mRNA-based vaccination developed by BioNTech in less than a year was widely used to curb the spread of the virus and brought massive profits for the firm. BioNTech now focuses on cancer immunotherapies and aims to submit its first application for approval in the United States by the end of this year for a type of next-generation chemotherapy for uterine cancer. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Affordable GLP-1 Drugs For Weight Loss Are Within Reach
Affordable GLP-1 Drugs For Weight Loss Are Within Reach

Forbes

time27 minutes ago

  • Forbes

Affordable GLP-1 Drugs For Weight Loss Are Within Reach

Weight loss brings health benefits at any age, but is difficult for many to achieve and sustain. In every news cycle, there's at least one story about GLP-1 drugs such as Ozempic, Wegovy and Zepbound. Although some extol the drugs' health benefits, most focus on economics, including the drugs' high cost, the growing reluctance of private and public insurance plans to cover the expense and the resulting affordability crisis for patients. With a dose of common sense, we can solve these problems. American healthcare is too expensive. This is particularly true of brand-name drugs. Although our nation accounts for 4.2% of the world's population, we consume 13% of the world's prescription drugs and pay half of the world's costs for these products. GLP-1 drugs are a case in point. Federal labs and grant-funded university research produced many insights that led to new treatments. The discovery of glucagon-like peptide-1 receptor agonists (GLP-1RAs) grew out of National Institutes of Health and Veterans Administration research in the 1980s and '90s. The recent cuts to federal labs and university-based research programs may change this going forward. Building on this early work, Novo Nordisk developed, patented and secured FDA approval for two GLP-1 drugs to treat Type 2 diabetes: liraglutide and, a few years later, semaglutide. When semaglutide was approved to treat Type 2 diabestes in 2017, Novo named it Ozempic. Four years later, the FDA approved semaglutide at higher doses to treat obesity. Novo named the higher-dose version Wegovy. In 2022, Eli Lilly secured FDA approval of tirzepatide, its GLP-1 drug, to treat diabetes. It named the medication Mounjaro. The following year, the FDA approved higher doses of tirzepatide to treat obesity. Lilly named its higher-dose version Zepbound. Drug companies need FDA approval before they can market a newly patented drug. Unlike other countries, the FDA can't consider a new medication's price or the existence of equally effective, lower-cost alternatives in reaching its decision. Once FDA approval is secured, Medicare typically covers the the drug's cost because it is not allowed to negotiate with drug companies as other countries do. This policy was modified during the Biden administration, but only for a few brand-name drugs. It's the main reason the U.S. pays far higher prices than other countries. When a company brings a new product to market, it relies on patent law to protect its exclusivity. Although patents generally expire after 20 years, drug companies like Novo and Lilly use a variety of strategies to extend the lifespan of their patents or add secondary ones, according to Time magazine. Insulin was developed almost 100 years ago but Novo, Lilly and Sanofi still control 90% of the global insulin market. Novo has already extended its original patent on semaglutide to 2031. Lilly's patent on tirzepatide will not expire until 2036 (if then). An employee works on the production line at the Novo Nordisk factory in Hilleroed on September 26, ... More 2023. (Photo by SERGEI GAPON/AFP via Getty Images) When Novo and Lilly rolled out their new weight loss drugs, demand quickly outpaced production. This opened a regulatory door for federally licensed 503B compounding pharmacies to make products containing semaglutide or tirzepatide, the same active ingredients brand-name GLP-1 drugs. Their versions were not only more affordable; they offered flexible, individualized dosing. At the shortage's peak, 2 million Americans were using compounded GLP-1 drugs, according to Kaiser Health News. Despite this competition, Novo reaped a bonanza. U.S. spending on Ozempic and Wegovy surged to $38 billion in 2023 and reached $65 billion in 2024. Both companies poured billions into expanding their production as quickly as possible. In February 2025, the FDA declared the shortage was over. Soon thereafter, it notified compounders to wind down production. By restricting compounders, the FDA has transformed a production shortage into an affordability shortage. Medicare does not cover Wegovy or Zepbound for weight loss — only selected weight-related health problems after they develop. Private insurers are dropping coverage, or capping costs by erecting complex hurdles before they'll consider covering a GLP-1 drug. This year, 4.9 million people lost coverage of Zepbound in 2025, and 1.1 million lost coverage of Wegovy, according to GoodRx. If Medicaid is cut, the few states that currently cover GLP-1 drugs will probably stop. The administration and Congress could turn a blind eye to this problem, but voter patience is wearing thin. Fortunately, with one or two tweaks to policy, affordable weight-loss drugs are within reach. Although news articles about compounded GLP-1 drugs often refer to them using terms such as 'copycat,' 'cut-rate' or 'cheap," reputable compounders test the semaglutide and tirzepatide they use in their products to assure its quality and safety. Similar care is not always taken by importers of FDA-approved generic drugs. To address this concern, the FDA could urge, if not require, that all generic and compounded medications be independently tested to assure their quality and safety. The FDA or NIH should also conduct post-market surveillance of patients taking compounded GLP-1 drugs and compare their outcomes to those of patients taking brand-name products. This might reveal that the 'go low, go slow' approach that compounding allows reduces side effects, improves sustainment and achieves better results. Public and private health insurance is expensive because our healthcare system is hugely expensive. Rather than bankrupt the federal treasury or, alternatively, pass the costs on to states and tens of millions of American families, Congress should focus on lowering costs and improving the value of American healthcare. Overpriced GLP-1 drugs are a great place to start.

Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions
Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions

Business Wire

timean hour ago

  • Business Wire

Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions

NEW YORK--(BUSINESS WIRE)-- Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Ontellus, a leading provider of health records retrieval and claims intelligence from Aquiline, a private investment firm specializing in financial services and technology and Capstreet, a Houston-based lower middle market private equity firm. With this acquisition, Ontellus will join Datavant to deliver an integrated, digital-first platform that connects those with health records to those who need them easily, quickly and securely. In addition to driving value to providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process. The combined organization will reduce administrative burden for Datavant's network of over 80,000 health care providers, clinics, hospitals and health system partners, who routinely manage requests for health records—vital for life insurance underwriting, injury claims, and legal case work. Today, the record retrieval process remains highly fragmented, with inconsistent workflows, procedures, and data formats across thousands of organizations. By joining forces, Datavant and Ontellus reaffirm their shared commitment to simplify this complexity and improve access to records to ensure that confidential health records are digitized in a secure and timely manner to authorized parties. 'Moving health data securely and compliantly from where it sits to where it needs to be in the right format to authorized users is one of the industry's biggest challenges,' said Datavant CEO Kyle Armbrester. 'In addition to driving value to our health care providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process that leverages Datavant's deep expertise in privacy preservation and compliance. We are delighted to welcome Ontellus' world-class team and work with them to further transform the health data request process for all of our customers.' Ontellus has digitized its records retrieval business into a nationwide platform through which record requestors have direct access to providers. Additionally, through its canvassing services, Ontellus delivers detailed claimant treatment timelines to validate claims or uncover preexisting conditions, helping customers reduce unnecessary and costly claims exposure. Datavant will join Ontellus' capabilities with its own digital connectivity capabilities to create a highly tech-enabled integrated platform offering to better serve all customers. Ontellus CEO, Vince Cole, will join Datavant's Executive Leadership Team, reporting directly to Kyle Armbrester, Datavant CEO. 'By combining Ontellus' industry-leading request fulfillment infrastructure with Datavant's advanced connectivity and data exchange capabilities, we're enabling faster, more precise access to critical health information—not only for healthcare providers, but also for legal and insurance professionals who rely on timely, accurate data to support claims and compliance. We are deeply grateful to our investor partners, Aquiline Capital Partners and The Capstreet Group, whose strategic guidance and resources have powered our growth and product innovation,' said Vince Cole, CEO of Ontellus. Houlihan Lokey served as buyside financial advisor to Datavant, assisting in evaluating and negotiating the acquisition. Harris Williams is the sell-side advisor to Ontellus, representing the company in its pending sale to Datavant. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Ontellus Ontellus empowers insurance carriers, self-insured corporations and law firms to reduce costs, make informed decisions and accelerate claims resolution. As one of the nation's largest, privately held data retrieval and claims intelligence providers, Ontellus leverages decades of experience and cutting-edge technology to deliver impactful products and client-centric services with industry-leading turnaround times. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store